What is William Blair's Forecast for PTCT FY2025 Earnings?

Key Points

• William Blair has cut its FY2025 earnings estimate for PTC Therapeutics from $6.46 to $6.40 per share.
• PTC Therapeutics recently reported a quarterly loss of ($0.83) EPS, which was better than the consensus estimate of ($1.07).
• Several brokerages have lowered their price targets on PTC Therapeutics shares, with JPMorgan cutting their target from $75 to $67 and Bank of America from $82 to $76.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at William Blair lowered their FY2025 earnings per share estimates for shares of PTC Therapeutics in a research note issued to investors on Tuesday, August 19th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will post earnings of $6.40 per share for the year, down from their prior forecast of $6.46. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics' Q4 2025 earnings at ($1.29) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.58) EPS and FY2026 earnings at ($2.90) EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.24. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The company had revenue of $178.88 million for the quarter, compared to the consensus estimate of $173.01 million. During the same quarter in the previous year, the business earned ($1.29) EPS. PTC Therapeutics's revenue was down 4.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS.

Other research analysts also recently issued research reports about the company. Wells Fargo & Company reduced their target price on PTC Therapeutics from $79.00 to $73.00 and set an "overweight" rating on the stock in a report on Wednesday, August 20th. Bank of America reduced their target price on PTC Therapeutics from $82.00 to $76.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Royal Bank Of Canada reiterated an "outperform" rating and set a $63.00 target price (up previously from $60.00) on shares of PTC Therapeutics in a report on Friday, August 8th. Citigroup upped their target price on PTC Therapeutics from $40.00 to $50.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Finally, UBS Group upped their target price on PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $69.15.

PTC Therapeutics Price Performance

NASDAQ:PTCT traded down $0.66 during mid-day trading on Thursday, reaching $48.64. 223,130 shares of the company's stock traded hands, compared to its average volume of 1,081,200. PTC Therapeutics has a 12-month low of $30.41 and a 12-month high of $58.38. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of 6.98 and a beta of 0.54. The company has a 50 day moving average price of $48.81 and a 200-day moving average price of $49.03.

Insider Buying and Selling at PTC Therapeutics

In other news, CFO Pierre Gravier sold 2,516 shares of the stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total transaction of $124,441.36. Following the transaction, the chief financial officer directly owned 71,920 shares of the company's stock, valued at $3,557,163.20. This represents a 3.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthew B. Klein sold 10,739 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $51.74, for a total value of $555,635.86. Following the transaction, the chief executive officer directly owned 337,767 shares in the company, valued at $17,476,064.58. The trade was a 3.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in shares of PTC Therapeutics by 424.4% during the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 522 shares during the period. Quantbot Technologies LP lifted its position in PTC Therapeutics by 545.5% during the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 551 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in PTC Therapeutics by 84.2% during the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 320 shares in the last quarter. GAMMA Investing LLC lifted its position in PTC Therapeutics by 86.3% during the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 441 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in PTC Therapeutics by 247.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 814 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.